Key points are not available for this paper at this time.
= 121 and 49 cases). Overall, GAGomes appeared to be powerful MCED metabolic biomarkers, potentially doubling the number of stage I cancers detectable using genomic biomarkers.
Bratulić et al. (Mon,) studied this question.